We are incredibly honored to share that Tom Doyle has joined RIS Rx as a Senior Advisor.
For those who know Tom’s career – and many of you do – you understand the weight of this moment. For those who don’t, allow me to introduce someone who has helped shape the commercial and biopharma services landscape at companies like Cencora, EVERSANA, and H.D. Smith for decades. This is not an announcement we take lightly. It is one we are genuinely humbled by.
Stephen and I have known Tom for over a decade. We first crossed paths as two pharmacists who had seen firsthand what happens when patients arrive at the pharmacy counter believing their medication is covered, only to discover that their copay funds had vanished into a maze of accumulators, maximizers, or systemic inefficiencies. We were convinced there was a different, better way to solve patients’ affordability problems, and we built RIS Rx around that conviction.
Tom saw that conviction early. Long before RIS Rx had the track record it has today, he recognized what we were trying to do and why it mattered. Over the years, he has been one of the most steadying, thoughtful, and insightful voices in our corner – and we have learned a great deal from him.
He recently joined us on the GTN Edge, our new podcast dedicated to unpacking the $90 billion GTN problem facing pharmaceutical manufacturers. In that conversation, Tom said something that has stayed with us: “Seldom in your career do you encounter a business with a 95 Net Promoter Score.” That is what he saw in RIS Rx – and now he is part of building what comes next.
We are proud to have Tom with us on the ground at Asembia next week, and we cannot wait for the industry to experience what his partnership means for our clients and our mission.
To read the full announcement, visit the press release on Business Wire.
Welcome, Tom. Truly honored.
